<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01210079</url>
  </required_header>
  <id_info>
    <org_study_id>R01 DA 05463</org_study_id>
    <nct_id>NCT01210079</nct_id>
  </id_info>
  <brief_title>Hyperalgesia in Methadone-Maintained Patients: Can it be Treated?</brief_title>
  <official_title>Hyperalgesia in Methadone-Maintained Patients: Can it be Treated?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Utilizing a double-blind, placebo-controlled design, the proposed work will evaluate the
      ability of an adjuvant anticonvulsant analgesic to diminish or reverse the opioid-induced
      hyperalgesia complicating the pain states suffered by Methadone-Maintained (MM) patients.
      Specifically, in a sample of MM patients, gabapentin, which has proven efficacy in treating
      neuropathic pain will be evaluated for its ability to ameliorate or diminish the
      opioid-induced hyperalgesia in these patients as reflected by changes on pain threshold and
      tolerance to both cold-pressor and electrical pain, at peak and through methadone blood
      levels. The results of this work will not only provide pharmacologic insight into the
      mechanisms underlying poor pain tolerance in this at-risk population, but also direction for
      the medical management of pain complicated by opioid-induced hyperalgesia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pain Threshold Time From Baseline to Week 5</measure>
    <time_frame>baseline, 5 weeks</time_frame>
    <description>Change in pain threshold time from baseline (pre-gabapentin) to week 5 (post gabapentin)measured during cold pressor task administered at peak methadone blood levels. Pain threshold time is the amount of time that passes before pain is detected after administration of the cold pressor.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Opioid-Induced Hyperalgesia</condition>
  <arm_group>
    <arm_group_label>Gabapentin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin;</intervention_name>
    <description>Gabapentin titrated to daily dose of 2400mg PO over 1 week with established dose taken daily for 5 weeks.</description>
    <arm_group_label>Gabapentin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo titrated over 1 week with established dose taken daily for 5 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Potential participants must:

          1. Be between the ages of 21 and 55 years of age.

          2. DSM-IVR diagnosis of prescription opioid abuse or dependence disorder

          3. Be compliant in methadone treatment

          4. On a stable dose of methadone at least 6 weeks.

          5. Have provided random urine samples absent of any non-prescribed drugs of abuse x 2
             months

          6. Be in good physical health or in the case of a medical condition needing ongoing
             treatment, be in the care of a physician who is willing to take responsibility for
             such treatment. The same conditions apply in cases of patients with a psychiatric
             disorder needing ongoing treatment.

          7. Be agreeable to and capable of signing an informed consent.

        Exclusion Criteria:

        Potential participants must not:

          1. Have known sensitivity to gabapentin.

          2. Be substance dependent on alcohol, benzodiazepine, methamphetamine, cocaine or other
             drugs of abuse (except nicotine).

          3. Have any acute medical condition that would make participation medically hazardous,
             (e.g., acute hepatitis, unstable cardiovascular disease, liver or renal disease) or
             have liver enzyme values (AST or ALT) greater than 5 times normal range.

          4. Be acutely psychotic, severely depressed and in need of inpatient treatment, or an
             immediate suicide risk.

          5. Have a neurological or psychiatric illness (i.e., schizophrenia, Raynaud's disease,
             urticaria, stroke) that would affect pain responses.

          6. Be currently taking opioid analgesic medication for a painful condition on a regular
             basis.

          7. Be a nursing or pregnant female. Female of childbearing potential must agree to use a
             medically acceptable method of birth control, (e.g. oral contraceptives, barrier
             (diaphragm or condom) with or without spermicide, levonorgestrel implant,
             intra-uterine progesterone contraceptives system, medroxyprogesterone acetate
             contraceptive injection) or to complete abstinence. Females who become pregnant during
             the course of the study will be dropped from the study.

          8. Have a current or past history of high blood pressure, heart disease, stroke or
             currently have a pacemaker.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret (Peggy) A Compton, RN, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA School of Nursing</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2010</study_first_submitted>
  <study_first_submitted_qc>September 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2010</study_first_posted>
  <results_first_submitted>December 5, 2011</results_first_submitted>
  <results_first_submitted_qc>March 11, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 6, 2012</results_first_posted>
  <last_update_submitted>March 11, 2012</last_update_submitted>
  <last_update_submitted_qc>March 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Peggy Compton</investigator_full_name>
    <investigator_title>Professor, Associate Dean for Academic Affairs</investigator_title>
  </responsible_party>
  <keyword>opioid-induced hyperalgesia</keyword>
  <keyword>methadone</keyword>
  <keyword>gabapentin</keyword>
  <keyword>opioid addiction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperalgesia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Methadone</mesh_term>
    <mesh_term>gamma-Aminobutyric Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Gabapentin</title>
          <description>Gabapentin titrated to 2400 mg daily PO for 5 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Matched placebo group underwent identical 'titration' as intervention group.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gabapentin</title>
          <description>Gabapentin titrated to 2400 mg daily PO for 5 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Matched placebo group underwent identical 'titration' as intervention group.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.5" spread="4.46"/>
                    <measurement group_id="B2" value="49.5" spread="4.96"/>
                    <measurement group_id="B3" value="47.9" spread="5.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Pain Threshold Time From Baseline to Week 5</title>
        <description>Change in pain threshold time from baseline (pre-gabapentin) to week 5 (post gabapentin)measured during cold pressor task administered at peak methadone blood levels. Pain threshold time is the amount of time that passes before pain is detected after administration of the cold pressor.</description>
        <time_frame>baseline, 5 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gabapentin</title>
            <description>Gabapentin titrated to 2400 mg daily PO for 5 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo group underwent identical 'titration' as intervention group.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain Threshold Time From Baseline to Week 5</title>
          <description>Change in pain threshold time from baseline (pre-gabapentin) to week 5 (post gabapentin)measured during cold pressor task administered at peak methadone blood levels. Pain threshold time is the amount of time that passes before pain is detected after administration of the cold pressor.</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.95" spread="2.41"/>
                    <measurement group_id="O2" value="-3.49" spread="2.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Gabapentin</title>
          <description>Gabapentin titrated to 2400 mg daily PO for 5 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Matched placebo group underwent identical 'titration' as intervention group.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Baseline hyperalgesia not established. Duration of trial only 5 weeks. Findings can only be generalized to methadone-maintained patients who are able to abstain from illicit drug use over an extended period of time.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Margaret (Peggy) Compton, RN PhD</name_or_title>
      <organization>School of Nursing, University of California, Los Angeles</organization>
      <phone>(310) 206-2825</phone>
      <email>pcompton@sonnet.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

